AstraZeneca’s Farxiga Fast Track’d for CV benefit claim

The FDA designates AstraZeneca’s (NYSE:AZN) Farxiga (dapagliflozin) for Fast Track review for reducing the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

The FDA approved the SGLT2 inhibitor in January 2014 to improve blood sugar control in type 2 diabetics.

https://seekingalpha.com/news/3499384-astrazenecas-farxiga-fast-trackd-cv-benefit-claim